6
Oct
2026
Pharmascience
Exhibitor at CPHI Milan 2026 stand 18B41, Finished Dosage & Formulation
About Us
Categories
-
Country/Region:Canada
-
On CPHI since:2015
-
Certificates:3
-
Employees:1000 - 4999
Company types
Primary activities
Event information
CPHI Milan 2026
-
6 Oct 2026 - 8 Oct 2026
-
Fiera Milano, Italy
-
Visit us at stand 18B41, Finished Dosage & Formulation
Products Featured at CPHI Milan 2026
-
Product MyInfla
Pharmascience Inc provides a wide range of key products which includes MyInfla. Form: colchicine extended-release tablets. MYINFLA is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies... -
Product Olican
Pharmascience Inc provides a wide range of key products which includes Olican. Form: Capsules of 0.5 mg of fingolimod (as fingolimod hydrochloride). OLICAN is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to r... -
Product Contract Development Manufacturing Services
Our expert R&D and manufacturing team delivers FDA & EMA approved turnkey solutions delivering CDMO and CMO competitive advantages for sterile cytotoxic injectables and solid dosage forms. -
Product Analytical Laboratory Services
Royalmount Laboratories boast a purpose-built, partially automated, state-of-the-art GLP certified and FDA inspected laboratory. This laboratory provides robust bioanalytical method development and validation for quantification of drugs and metabolites in biological fluids/tissu... -
Product Finished Dosage Form
Our approvals from active members of ICH and PIC/s, including Health Canada, US FDA and EMA ensuring the safest , most effective and highest-quality medicines are developed compliant with the highest international regulations.
